|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||2.9500 - 3.2500|
|52 Week Range||2.6300 - 4.4300|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, Jan. 15, 2021 /CNW/ - Friday 15/01/2021PICK-2: 7 8 PICK-3: 7 0 3 PICK-4: 7 2 5 9 ENCORE: 1099158 DAILY KENO 1, 3, 7, 12, 17, 21, 22, 26, 27, 31, 34, 39, 43, 50, 52, 55, 59, 60, 63, 68.
FINTOP Capital Leads Investment With General Partner John Philpott Joining Qohash's Board of DirectorsQUEBEC CITY,QC, Jan. 14, 2021 /CNW/ - As industries continue to face economic upheaval in the wake of COVID-19, data security startup Qohash has announced raising CAD 8 million in a Series A round of funding led by FINTOP Capital.
MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.